✦ LIBER ✦

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

✍ Scribed by Lathia, CD; Amakye, D; Dai, W; Girman, C; Madani, S; Mayne, J; MacCarthy, P; Pertel, P; Seman, L; Stoch, A

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biomarkers and Surrogate End Points for

✍ Wagner, J A; Williams, S A; Webster, C J 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 74 KB

On the use of surrogate end points in ra

✍ C. B. Begg; D. H. Y. Leung 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB

THE PROMISE AND PERIL OF SURROGATE END P

✍ Schatzkin, Arthur; Gail, Mitchell 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 263 KB

Statistical methods for clinical studies

✍ Denis Heng-Yan Leung 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB

Assessing proliferation, cell-cycle arre

✍ Camidge, D R; Pemberton, M N; Growcott, J W; Johnstone, D; Laud, P J; Foster, J 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 230 KB

Chutes and Ladders on the Critical Path:

✍ Woodcock, J 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 67 KB